Get started
Author

Nishi Jain

Observed institution: Seagen (United States)
ORCID: 0009-0006-8438-9376
Observed ORCID: 0009-0006-8438-9376
OpenAlex ID: A5023757153
HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al. · Cancer Research Communications · 37
PDF
Abstract PS10-08: Tucatinib potentiates the activity of the antibody-drug conjugate T-DM1 in preclinical models of HER2-positive breast cancer
2021 · Anita Kulukian, Janelle Taylor, et al. · Cancer Research · 5
Figure S2 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Data from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
FIGURE 1 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
FIGURE 5 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Figure S1 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Data from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
FIGURE 6 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Figure S2 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
FIGURE 1 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
FIGURE 3 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
FIGURE 4 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Figure S1 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
FIGURE 2 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
FIGURE 5 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
FIGURE 4 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Figure S6 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Figure S5 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Figure S6 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Figure S4 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Supplementary Materials and Methods from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Figure S3 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Figure S4 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Figure S5 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Works count: 26
Citation count: 42
H-index: 2
I10-index: 1
Year
Topic
Type